Table 2.
Demographic and clinical characteristics of patients and samples included in analysis, stratified by CLAD status at time of BAL
| Variable | All (n=154) | CLAD-Free (n=77) | CLAD Onset (n=77) | p-value1 |
|---|---|---|---|---|
| Age in years, n (%) | 0.746 | |||
| Less than 30 | 27 (17.5) | 12 (15.6) | 15 (19.5) | |
| 30–40 | 12 (7.8) | 5 (6.5) | 7 (9.1) | |
| 40–50 | 16 (10.4) | 7 (9.1) | 9 (11.7) | |
| 50–60 | 64 (41.6) | 36 (46.8) | 28 (36.4) | |
| Older than 60 | 35 (22.7) | 17 (22.1) | 18 (23.4) | |
| Female sex, n (%) | 56 (36.4) | 20 (26.0) | 36 (46.8) | 0.007 |
| Pre-Transplant Diagnosis, n (%) | 0.281 | |||
| COPD/Emphysema | 39 (25.3) | 19 (24.7) | 20 (26.0) | |
| ILD | 66 (42.9) | 38 (49.4) | 28 (36.4) | |
| Cystic Fibrosis | 26 (16.9) | 12 (15.6) | 14 (18.2) | |
| Other | 23 (14.9) | 8 (10.4) | 15 (19.5) | |
| Bilateral Lung Transplant, n (%) | 106 (68.8) | 50 (64.9) | 56 (72.7) | 0.297 |
| BAL Performed for Surveillance, n (%) | 13 (8.4) | 9 (11.7) | 4 (5.2) | 0.147 |
| Days BAL after Lung Transplant, mean ± SD | 1016 ± 748 | 1002 ± 723 | 1030 ± 776 | 0.543 |
| Concurrent ACR biopsy grade ≥A12, n (%) | 20 (13.0) | 9 (11.7) | 11 (14.3) | 0.632 |
| Concurrent LB biopsy grade ≥B1R2, n (%) | 7 (4.6) | 3 (3.9) | 4 (5.2) | 0.699 |
| DSA Present3,4, n (%) | 31 (30.4) | 11 (23.9) | 20 (35.7) | 0.197 |
| BAL Neutrophils >15%2,5, n (%) | 79 (54.5) | 31 (43.1) | 48 (65.8) | 0.006 |
| Positive Bacterial Culture, n (%)2,6 | 21 (13.8) | 9 (11.8) | 12 (15.8) | 0.481 |
| Positive Respiratory Virus PCR, n (%)2,7 | 5 (4.6) | 3 (5.7) | 2 (3.5) | 0.588 |
Definition of abbreviations: CLAD = chronic lung allograft dysfunction, COPD = chronic obstructive pulmonary disease, ILD = interstitial lung disease, BAL = bronchioalveolar lavage, ACR = acute cellular rejection, LB = lymphocytic bronchiolitis, PCR = polymerase chain reaction qualitative test
Comparing CLAD-Free vs. CLAD Onset groups
Identified on bronchoscopy from which the mesenchymal CFU count was measured
DSA presence was defined as mean fluorescence intensity of ≥1000 on single bead antigen testing prior to bronchoscopy
n=102, 31 missing from CLAD Free group, 21 missing from CLAD onset group
n=145, 5 missing from CLAD free group, 4 missing from CLAD onset group
n=152, 1 missing from CLAD free group, 1 missing from CLAD onset group
n=110, 24 missing from CLAD free group, 20 missing from CLAD onset group